COSTEM 2023 | Reduced intensity vs myeloablative conditioning regimens in patients with AML and MDS
Daniele Avenoso, MD, King’s College Hospital NHS Foundation Trust, London, UK, evaluates the use of reduced intensity conditioning (RIC) vs myeloablative conditioning (MAC) regimens in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) depending on their HCT-CI score. This interview took place at The 8th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM 2023), held in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honorarium for advisory boards from Sanofi, honorarium for speaking for Sanofi, Honorarium for consultancy from Sanofi, Travel grant from Sanofi
Honorarium for speaking fromMallinckrodt/Therakos
Honorarium for speaking and travel grant from Medac Pharma
